astrazeneca hit drug failure shares anglo-swedish drug closed 8 uk trade failure iressa drug major clinical trial lung cancer drug significantly prolong survival patients disease setback group follows rejection october anti-coagulant pill exanta major money spinners cholesterol drug crestor facing mounting safety concerns blockbuster drugs meant power company forward failing 've got risks crestor said nick turner analyst brokers jefferies astrazeneca hoped pitch iressa drug rival medicine tarceva iressa proved better placebo extending lives trial involving 1,692 patients tarceva osi pharmaceuticals genentech roche proved successful helping prolong life lung cancer patients aztrazeneca appointed new executive director board john patterson charge drug development company said mr patterson substantial changes clinical organisation processes determined improve development regulatory performance restore confidence company value shareholders said chief executive tom mckillop 